Bupyra Xl 150 & 300 150mg, 300mg EXTENDED-RELEASE TABLET
PDF Leaflet Revision Date: 23 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of depression as defined by DSM IV Criteria.
Dosage (summary)
Initial: 150 mg once daily; may increase to 300 mg once daily if needed.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; avoid breastfeeding.
Key Drug Interactions
- MAOIs
- CYP2D6 inhibitors
- Serotonergic medicines
Contraindications
- Hypersensitivity to bupropion
- Seizure disorder
- Patients under 18 years
- Bulimia or anorexia nervosa
- Moderate to severe hepatic cirrhosis
Common side effects
- Insomnia
- Dry mouth
- Headache
- Increased blood pressure
Counselling Points
- Swallow tablets whole, do not crush or chew.
- Monitor for worsening depression or suicidal thoughts.
- Avoid alcohol during treatment.
Serious warnings
- Risk of seizures
- Suicidal thoughts
- Neuropsychiatric symptoms
Important Disclaimer
The Bupyra Xl 150 & 300 150mg, 300mg EXTENDED-RELEASE TABLET professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
